Artgen Biotech PJSC (MIC:ABIO) Cash And Cash Equivalents : ₽362 Mil (As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC Cash And Cash Equivalents?

Artgen Biotech PJSC's quarterly cash and cash equivalents increased from Jun. 2022 (₽59.40 Mil) to Dec. 2022 (₽201.66 Mil) and increased from Dec. 2022 (₽201.66 Mil) to Jun. 2023 (₽361.71 Mil).

Artgen Biotech PJSC's annual cash and cash equivalents increased from Dec. 2020 (₽107.39 Mil) to Dec. 2021 (₽193.29 Mil) and increased from Dec. 2021 (₽193.29 Mil) to Dec. 2022 (₽201.66 Mil).

Artgen Biotech PJSC Cash And Cash Equivalents Historical Data

The historical data trend for Artgen Biotech PJSC's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC Cash And Cash Equivalents Chart

Artgen Biotech PJSC Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

64.41

89.75

107.39

193.29

201.66

Artgen Biotech PJSC Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash And Cash Equivalents	Get a 7-Day Free Trial															48.53	193.29	59.40	201.66	361.71

Artgen Biotech PJSC Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Artgen Biotech PJSC (MIC:ABIO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Artgen Biotech PJSC Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Artgen Biotech PJSC (MIC:ABIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Prospect of the 60th Anniversary, Moscow, RUS, 117036

Website

https://www.hsci.ru

Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.